Harmony Biosciences is trading at $36.63 (4.1% down) amid ongoing volatility tied to Wakix patent litigation and shifting analyst views on long-term exclusivity.
- Mizuho recently reiterated its Outperform rating and $50 price target following a favorable review of trial transcripts, which had initially boosted the stock.
- Investors appear to be reassessing litigation risks and future cash-flow durability, leading to profit-taking and downward pressure on shares.